Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Overview of attention for article published in Alzheimer's Research & Therapy, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#50 of 1,500)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 16 news outlets
blogs: 1 blog

twitter: 5 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 56 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 8 X posts from 5 X users, with an upper bound of 84,765 followers.

https://t.co/PRXv30CdAq

19 Apr 2021

Reply Repost Favourite

A study published in @AlzheimersRes indicates that GV1001 may have beneficial effects on the cognition and activities of patients with moderate-to-severe Alzheimer’s disease who are already receiving donepezil. https://t.co/MUXXMyMQqz

11 Apr 2021

Reply Repost Favourite

RT @DDNewsOnline: #GemVax touts safety & efficacy of GV1001 in Ph2 #ClinicalTrials vs #Alzheimer’s disease #Neuroprotective #peptide impro…

06 Apr 2021

Reply Repost Favourite

RT @BioMedCentral: A study published in @AlzheimersRes indicates that GV1001 may have beneficial effects on the cognition and activities of…

06 Apr 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.